-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Izotropic's Breast CT Radiation Imaging Subsystem Powered on and Takes Initial Images
Izotropic's Breast CT Radiation Imaging Subsystem Powered on and Takes Initial Images
VANCOUVER, BC - TheNewswire - November 22, 2021 - Izotropic Corporation ("Izotropic" or the "Company") (CNSX:IZO.CN) (OTC:IZOZF) (FSE:1R3), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers provides updates on the following:
- IzoView radiation imaging subsystem assembly, functionality, and installation features
- Formal radiation safety certification
- Initial phantom image acquisition and image reconstruction software
Izotropic is pleased to announce that its engineering teams have successfully built and assembled IzoView's radiation imaging subsystem, and it has been formally certified as safe to operate. This milestone enables the subsystem, which is now taking static images, to be characterized and optimized for 360-degree image acquisition.
Radiation Imaging Subsystem: Safety and minimized installation costs
IzoView's radiation imaging subsystem has been powered on, tested, and emits less radiation into the surrounding area than diagnostic mammography. A formal radiation safety certification was awarded upon completion of radiation safety testing that was conducted by the governing health authority.
Radiation safety testing is completed by measuring the amount of radiation output into the surrounding area or imaging suite during a single scan. Radiation-based imaging devices typically require a radiation-safe leaded room or a leaded divider for the technician to stand behind during the scan. Certain levels of radiation leakage that result from radiation-based imaging devices into the imaging suite are allowable under standard safety requirements, but measures must be taken to protect patients and staff with increased installation and set up costs to the customer. IzoView has been designed with specific features to minimize customer installation and shielding costs while providing enhanced patient and technician safety.
IzoView's Initial Images
The radiation imaging subsystem is now acquiring and producing preliminary images. Images have been taken using different types of phantoms which are stand-in objects in place of human tissue. Phantoms have been used to calibrate the imaging system in relation to the detector and the geometry of the imaging system for the 3D reconstruction software.
With this milestone achieved, engineering teams can now begin optimizing and calibrating the imaging subsystem to acquire images in 360 degrees- the key differentiator for IzoView's true 3D images versus 2D mammography or tomosynthesis images.
The preliminary image data being produced will support the advancement of the new image reconstruction software that utilizes deep machine learning algorithms currently in development in partnership with Johns Hopkins University School of Medicine.
Phantom image acquisition, which was initially projected to begin in Q1 2022, has begun ahead of schedule.
Messages from CEO and EVP of Product Engineering
"This next stage is really about fine-tuning key variables in our hardware and software upgrades as they work together to create the high-resolution 3D images our Breast CT system offers," said Dr. Younes Achkire, Executive Vice President of Product Engineering. "We're doing this so when we ramp up to production for our clinical study units, our images and device operation will be 100% consistent."
CEO, Dr. John McGraw, stated: "Even with ongoing global supply chain issues, we have our key components: generator, power unit, detector, and computer, and we can power it all on and produce images. I'm very proud of what we're continuing to accomplish at Izotropic."
ON BEHALF OF THE BOARD
For investor relations inquiries, contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward-Looking Statements
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.
温哥華,公元前-新聞通訊社-2021年11月22日-各向同性公司("各向同性“或”公司") (CNSX:以藏。氯化萘)(場外交易:IZOZF)(FSE:1R3), 一家公司將專用乳腺CT(計算機斷層掃描)成像平臺IzoView商業化,以便更準確地檢測和診斷乳腺癌,提供了以下方面的最新信息:
-IzoView輻射成像子系統組件、功能和安裝特性
-正式的輻射安全認證
-初始模型圖像採集和圖像重建軟件
Izotroy公司高興地宣佈,它的工程團隊已經成功地建造和組裝了IzoView的輻射成像子系統,並且它已經被正式認證為可以安全操作。這一里程碑使目前正在拍攝靜態圖像的子系統能夠針對360度圖像採集進行特徵化和優化。
輻射成像子系統:安全性和最低安裝成本
IzoView的輻射成像子系統已經開機、測試,向周圍區域發射的輻射比診斷性乳房X光檢查要少。在完成由主管衞生當局進行的輻射安全測試後,頒發了正式的輻射安全證書。
輻射安全測試是通過測量單次掃描期間輸出到周圍區域或成像套件的輻射量來完成的。基於輻射的成像設備通常需要一個防輻射的引線房間或引線隔板,以便技術人員在掃描期間站在後面。根據標準安全要求,基於輻射的成像設備進入成像套件所導致的一定程度的輻射泄漏是允許的,但必須採取措施保護患者和工作人員,增加安裝,並增加客户的設置成本。IzoView的設計具有特定功能,可將客户安裝和屏蔽成本降至最低,同時提高患者和技術人員的安全性。
IzoView的初始圖像
輻射成像子系統現在正在採集和產生初步圖像。已經使用不同類型的模體來拍攝圖像,這些模體是代替人體組織的替身對象。已經使用模體相對於探測器和3D重建軟件的成像系統的幾何形狀來校準成像系統。
隨着這一里程碑的實現,工程團隊現在可以開始優化和校準成像子系統,以獲得360度的圖像-這是IzoView真正的3D圖像與2D乳房X光檢查或斷層合成圖像的關鍵區別。
正在製作的初步圖像數據將支持新圖像重建軟件的發展,該軟件利用目前正在與約翰·霍普金斯大學醫學院合作開發的深度機器學習算法。
幻影圖像採集最初計劃於2022年第一季度開始,現在已經提前開始。
來自首席執行官兼產品工程執行副總裁的信息
產品工程部執行副總裁尤尼斯·阿奇基爾博士説:“下一階段實際上是對硬件和軟件升級中的關鍵變量進行微調,因為它們將共同創建我們的乳房CT系統提供的高分辨率3D圖像。”我們這樣做是為了當我們的臨牀研究單位逐步投產時,我們的圖像和設備操作將百分之百一致。“
首席執行官約翰·麥格勞博士説:“儘管全球供應鏈問題仍在繼續,但我們有我們的關鍵部件:發電機、動力裝置、探測器和計算機,我們可以為它們通電並生成圖像。我為我們在Izotroal公司繼續取得的成就感到非常自豪。”
我代表董事會
有關投資者關係的查詢,請聯繫:
電子郵件:jberard@izocorp.com
電話:778-228-2314
免費電話:1-833-IZOCORP分機1
關於Izotroal公司
Izotroy公司是唯一一家將專用乳腺CT成像平臺IzoView商業化的上市公司,該平臺用於更準確地檢測和診斷乳腺癌。為了加快患者和供應商使用IzoView的速度,Izotroy的初步臨牀研究打算證明診斷性乳房CT成像的性能優於診斷性乳房X光檢查程序,並將於2022年第二季度啟動。在後續的臨牀研究中,Izotrotic公司打算驗證平臺應用,包括放射學中的乳房篩查、外科腫瘤學中的治療計劃和監測,以及整形和重建外科中的乳房重建和植入物監測。
欲瞭解有關Izotroy公司的更多信息,請訪問該公司的網站:izocorp.com。並通過在SEDAR上查看其個人資料Sedar.com
前瞻性陳述
本文件可能包含“前瞻性陳述”,這些陳述基於對公司管理層、業務的當前估計、假設、預測和預期,以及對公司運營所處的相關市場和經濟環境的瞭解。在可能的情況下,公司已嘗試通過使用諸如“預期”、“相信”、“設想”、“估計”、“預期”、“打算”、“可能”、“計劃”、“預測”、“計劃”、“預測”、“項目”、“目標”、“潛在”、“將會”、“將會”、“可能”、“應該”、“繼續”等詞語來識別此類信息和陳述。關於未來事件、趨勢或前景或未來經營或財務表現的任何討論,“設想”及其他類似表述及其派生,儘管並非所有前瞻性表述都包含這些識別詞彙。這些陳述不是對業績的保證,涉及難以控制或預測的風險和不確定因素,因此,它們可能導致公司未來活動的結果與此類陳述的內容和影響大不相同。前瞻性陳述僅在作出之日起具有相關性,除非法律另有要求,否則公司沒有義務更新或修改任何前瞻性陳述,以反映新信息或未來事件或情況的發生。本公司及其股東、高級管理人員和顧問均不對任何人根據本文包含的信息採取的任何行動以及任何行動的結果負責,包括但不限於購買或出售公司證券。本文檔中的任何內容都不應被視為任何類型的醫療或其他建議。
版權所有(C)2021 TheNewswire-保留所有權利。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧